Literature DB >> 27345369

HIV-1 Neutralizing Antibodies with Limited Hypermutation from an Infant.

Cassandra A Simonich1, Katherine L Williams2, Hans P Verkerke3, James A Williams3, Ruth Nduati4, Kelly K Lee3, Julie Overbaugh5.   

Abstract

HIV-1 broadly neutralizing antibodies (bnAbs) develop in a subset of infected adults and exhibit high levels of somatic hypermutation (SHM) due to years of affinity maturation. There is no precedent for eliciting highly mutated antibodies by vaccination, nor is it practical to wait years for a desired response. Infants develop broad responses early, which may suggest a more direct path to generating bnAbs. Here, we isolated ten neutralizing antibodies (nAbs) contributing to plasma breadth of an infant at ∼1 year post-infection, including one with cross-clade breadth. The nAbs bind to envelope trimer from the transmitted virus, suggesting that this interaction may have initiated development of the infant nAbs. The infant cross-clade bnAb targets the N332 supersite on envelope but, unlike adult bnAbs targeting this site, lacks indels and has low SHM. The identification of this infant bnAb illustrates that HIV-1-specific neutralization breadth can develop without prolonged affinity maturation and extensive SHM.
Copyright © 2016 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27345369      PMCID: PMC4930401          DOI: 10.1016/j.cell.2016.05.055

Source DB:  PubMed          Journal:  Cell        ISSN: 0092-8674            Impact factor:   41.582


  61 in total

1.  Somatic mutations of the immunoglobulin framework are generally required for broad and potent HIV-1 neutralization.

Authors:  Florian Klein; Ron Diskin; Johannes F Scheid; Christian Gaebler; Hugo Mouquet; Ivelin S Georgiev; Marie Pancera; Tongqing Zhou; Reha-Baris Incesu; Brooks Zhongzheng Fu; Priyanthi N P Gnanapragasam; Thiago Y Oliveira; Michael S Seaman; Peter D Kwong; Pamela J Bjorkman; Michel C Nussenzweig
Journal:  Cell       Date:  2013-03-28       Impact factor: 41.582

2.  Rational design of envelope identifies broadly neutralizing human monoclonal antibodies to HIV-1.

Authors:  Xueling Wu; Zhi-Yong Yang; Yuxing Li; Carl-Magnus Hogerkorp; William R Schief; Michael S Seaman; Tongqing Zhou; Stephen D Schmidt; Lan Wu; Ling Xu; Nancy S Longo; Krisha McKee; Sijy O'Dell; Mark K Louder; Diane L Wycuff; Yu Feng; Martha Nason; Nicole Doria-Rose; Mark Connors; Peter D Kwong; Mario Roederer; Richard T Wyatt; Gary J Nabel; John R Mascola
Journal:  Science       Date:  2010-07-08       Impact factor: 47.728

3.  Molecular characterization of five neutralizing anti-HIV type 1 antibodies: identification of nonconventional D segments in the human monoclonal antibodies 2G12 and 2F5.

Authors:  R Kunert; F Rüker; H Katinger
Journal:  AIDS Res Hum Retroviruses       Date:  1998-09-01       Impact factor: 2.205

4.  A broad range of mutations in HIV-1 neutralizing human monoclonal antibodies specific for V2, V3, and the CD4 binding site.

Authors:  Liuzhe Li; Xiao-Hong Wang; Constance Williams; Barbara Volsky; Olivia Steczko; Michael S Seaman; Kalpana Luthra; Phillipe Nyambi; Arthur Nadas; Véronique Giudicelli; Marie-Paule Lefranc; Susan Zolla-Pazner; Miroslaw K Gorny
Journal:  Mol Immunol       Date:  2015-05-18       Impact factor: 4.407

5.  HIV-1 VACCINES. Priming a broadly neutralizing antibody response to HIV-1 using a germline-targeting immunogen.

Authors:  Joseph G Jardine; Takayuki Ota; Devin Sok; Matthias Pauthner; Daniel W Kulp; Oleksandr Kalyuzhniy; Patrick D Skog; Theresa C Thinnes; Deepika Bhullar; Bryan Briney; Sergey Menis; Meaghan Jones; Mike Kubitz; Skye Spencer; Yumiko Adachi; Dennis R Burton; William R Schief; David Nemazee
Journal:  Science       Date:  2015-06-18       Impact factor: 47.728

6.  Passive immunotherapy in simian immunodeficiency virus-infected macaques accelerates the development of neutralizing antibodies.

Authors:  Nancy L Haigwood; David C Montefiori; William F Sutton; Janela McClure; Andrew J Watson; Gerald Voss; Vanessa M Hirsch; Barbra A Richardson; Norman L Letvin; Shiu-Lok Hu; Philip R Johnson
Journal:  J Virol       Date:  2004-06       Impact factor: 5.103

7.  The broadly neutralizing anti-human immunodeficiency virus type 1 antibody 2G12 recognizes a cluster of alpha1-->2 mannose residues on the outer face of gp120.

Authors:  Christopher N Scanlan; Ralph Pantophlet; Mark R Wormald; Erica Ollmann Saphire; Robyn Stanfield; Ian A Wilson; Hermann Katinger; Raymond A Dwek; Pauline M Rudd; Dennis R Burton
Journal:  J Virol       Date:  2002-07       Impact factor: 5.103

8.  Developmental pathway for potent V1V2-directed HIV-neutralizing antibodies.

Authors:  Nicole A Doria-Rose; Chaim A Schramm; Jason Gorman; Penny L Moore; Jinal N Bhiman; Brandon J DeKosky; Michael J Ernandes; Ivelin S Georgiev; Helen J Kim; Marie Pancera; Ryan P Staupe; Han R Altae-Tran; Robert T Bailer; Ema T Crooks; Albert Cupo; Aliaksandr Druz; Nigel J Garrett; Kam H Hoi; Rui Kong; Mark K Louder; Nancy S Longo; Krisha McKee; Molati Nonyane; Sijy O'Dell; Ryan S Roark; Rebecca S Rudicell; Stephen D Schmidt; Daniel J Sheward; Cinque Soto; Constantinos Kurt Wibmer; Yongping Yang; Zhenhai Zhang; James C Mullikin; James M Binley; Rogier W Sanders; Ian A Wilson; John P Moore; Andrew B Ward; George Georgiou; Carolyn Williamson; Salim S Abdool Karim; Lynn Morris; Peter D Kwong; Lawrence Shapiro; John R Mascola
Journal:  Nature       Date:  2014-03-02       Impact factor: 49.962

9.  Broad neutralization coverage of HIV by multiple highly potent antibodies.

Authors:  Laura M Walker; Michael Huber; Katie J Doores; Emilia Falkowska; Robert Pejchal; Jean-Philippe Julien; Sheng-Kai Wang; Alejandra Ramos; Po-Ying Chan-Hui; Matthew Moyle; Jennifer L Mitcham; Phillip W Hammond; Ole A Olsen; Pham Phung; Steven Fling; Chi-Huey Wong; Sanjay Phogat; Terri Wrin; Melissa D Simek; Wayne C Koff; Ian A Wilson; Dennis R Burton; Pascal Poignard
Journal:  Nature       Date:  2011-09-22       Impact factor: 49.962

10.  A next-generation cleaved, soluble HIV-1 Env trimer, BG505 SOSIP.664 gp140, expresses multiple epitopes for broadly neutralizing but not non-neutralizing antibodies.

Authors:  Rogier W Sanders; Ronald Derking; Albert Cupo; Jean-Philippe Julien; Anila Yasmeen; Natalia de Val; Helen J Kim; Claudia Blattner; Alba Torrents de la Peña; Jacob Korzun; Michael Golabek; Kevin de Los Reyes; Thomas J Ketas; Marit J van Gils; C Richter King; Ian A Wilson; Andrew B Ward; P J Klasse; John P Moore
Journal:  PLoS Pathog       Date:  2013-09-19       Impact factor: 6.823

View more
  73 in total

1.  Immunological mechanisms of inducing HIV immunity in infants.

Authors:  Genevieve G Fouda; Kristina De Paris; Ofer Levy; Arnaud Marchant; Glenda Gray; Sallie Permar; Mary Marovich; Anjali Singh
Journal:  Vaccine       Date:  2019-11-21       Impact factor: 3.641

Review 2.  Pediatric HIV: the Potential of Immune Therapeutics to Achieve Viral Remission and Functional Cure.

Authors:  Stella J Berendam; Ashley N Nelson; Ria Goswami; Deborah Persaud; Nancy L Haigwood; Ann Chahroudi; Genevieve G Fouda; Sallie R Permar
Journal:  Curr HIV/AIDS Rep       Date:  2020-06       Impact factor: 5.071

Review 3.  Deconstructing the Antiviral Neutralizing-Antibody Response: Implications for Vaccine Development and Immunity.

Authors:  Laura A VanBlargan; Leslie Goo; Theodore C Pierson
Journal:  Microbiol Mol Biol Rev       Date:  2016-10-26       Impact factor: 11.056

4.  Early Life HIV-1 Immunization: Providing a Window for Protection Before Sexual Debut.

Authors:  Sallie Permar; Ofer Levy; Tobias R Kollman; Anjali Singh; Kristina De Paris
Journal:  AIDS Res Hum Retroviruses       Date:  2018-07-03       Impact factor: 2.205

5.  VRC34-Antibody Lineage Development Reveals How a Required Rare Mutation Shapes the Maturation of a Broad HIV-Neutralizing Lineage.

Authors:  Chen-Hsiang Shen; Brandon J DeKosky; Yicheng Guo; Kai Xu; Ying Gu; Divya Kilam; Sung Hee Ko; Rui Kong; Kevin Liu; Mark K Louder; Li Ou; Baoshan Zhang; Cara W Chao; Martin M Corcoran; Eric Feng; Jesse Huang; Erica Normandin; Sijy O'Dell; Amy Ransier; Reda Rawi; Mallika Sastry; Stephen D Schmidt; Shuishu Wang; Yiran Wang; Gwo-Yu Chuang; Nicole A Doria-Rose; Bob Lin; Tongqing Zhou; Eli A Boritz; Mark Connors; Daniel C Douek; Gunilla B Karlsson Hedestam; Zizhang Sheng; Lawrence Shapiro; John R Mascola; Peter D Kwong
Journal:  Cell Host Microbe       Date:  2020-03-03       Impact factor: 21.023

Review 6.  The Neutralizing Antibody Response to the HIV-1 Env Protein.

Authors:  Penny L Moore
Journal:  Curr HIV Res       Date:  2018       Impact factor: 1.581

Review 7.  Env Exceptionalism: Why Are HIV-1 Env Glycoproteins Atypical Immunogens?

Authors:  P J Klasse; Gabriel Ozorowski; Rogier W Sanders; John P Moore
Journal:  Cell Host Microbe       Date:  2020-04-08       Impact factor: 21.023

8.  An HIV-1 Broadly Neutralizing Antibody from a Clade C-Infected Pediatric Elite Neutralizer Potently Neutralizes the Contemporaneous and Autologous Evolving Viruses.

Authors:  Harekrushna Panda; Muzamil Ashraf Makhdoomi; Nitesh Mishra; Sanjeev Kumar; Haaris Ahsan Safdari; Himanshi Chawla; Heena Aggarwal; Elluri Seetharami Reddy; Rakesh Lodha; Sushil Kumar Kabra; Anmol Chandele; Somnath Dutta; Kalpana Luthra
Journal:  J Virol       Date:  2019-02-05       Impact factor: 5.103

Review 9.  Targeting the N332-supersite of the HIV-1 envelope for vaccine design.

Authors:  Thandeka Moyo; Dale Kitchin; Penny L Moore
Journal:  Expert Opin Ther Targets       Date:  2020-04-27       Impact factor: 6.902

Review 10.  The antibody response in HIV-1-infected donors.

Authors:  Simone I Richardson; Penny L Moore
Journal:  Curr Opin HIV AIDS       Date:  2019-07       Impact factor: 4.283

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.